IN8BIO INC. - COMMON STOCK

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

07 May 2025 16:00:00 By Nasdaq GlobeNewswire

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

29 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

28 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

31 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

18 Mar 2025 08:05:00 By Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

13 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

03 Mar 2025 09:28:00 By Nasdaq GlobeNewswire

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

26 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

24 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

14 Feb 2025 09:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

11 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at Biotech Showcase 2025 in San Francisco

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

25 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

12 Nov 2024 16:26:01 By Nasdaq GlobeNewswire

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of $12.4 Million Private Placement

01 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

04 Sep 2024 16:01:00 By Nasdaq GlobeNewswire